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 CURRENTOPINION Development of encorafenib for BRAF-mutated
advanced melanoma
Peter Koelblingera,b, Olaf Thuerigenc, and Reinhard Dummera
Purpose of review
To describe the pharmacological properties, preclinical and clinical data of the novel V-Raf Murine
Sarcoma Viral Oncogene Homolog B (BRAF)-inhibitor encorafenib (LGX818) and to compare these with
established BRAF-inhibitors in the treatment of locally advanced or metastatic melanoma.
Recent findings
Encorafenib has shown improved efficacy in the treatment of metastatic melanoma in comparison with
vemurafenib. Combination with the MEK inhibitor (MEKi) binimetinib allows for higher dose intensities of
encorafenib further improving response rates (RRs).
Summary
Combination therapy with BRAF and MEKi has evolved as a standard of care in the treatment of locally
advanced or metastatic BRAFV600-mutated melanoma. Despite compelling initial RRs, development of
treatment resistance eventually leads to tumor progression in the majority of BRAF/MEK-inhibitor treated
patients. Moreover, treatment-related adverse events are frequent, resulting in a substantial proportion of
dose modifications and/or treatment discontinuations. The second-generation BRAF inhibitor encorafenib
has been developed aiming at improved efficacy and tolerability through modifications in pharmacological
properties. Clinical phase 3 data show improved progression-free survival both for encorafenib
monotherapy and combination therapy with binimetinib compared with vemurafenib. Overall survival data
and regulatory approval of this novel substance are eagerly awaited.
Keywords
binimetinib, BRAF-inhibitor, encorafenib, LGX818, melanoma
INTRODUCTION
The V-Raf Murine Sarcoma Viral Oncogene Homolog
B (BRAF) inhibitors (BRAFi) vemurafenib and dabra-
fenib have been used in everyday clinical practice for
the treatment of metastatic melanoma in (dermato-
)oncologic centers worldwide for more than 5 years.
Following initial regulatory approval of vemurafenib
and dabrafenib monotherapy in 2011 and 2013,
respectively [1,2], combination therapy with BRAF
and Mitogen-Activated Protein (MAP) Kinase/Extra-
cellular Signal-Regulated Kinase (ERK) kinase (MEK)
inhibitors(MEKi)subsequentlyreplacedBRAFimono-
therapy as a first-line therapeutic option in patients
with BRAF-mutated melanoma. Currently approved
combination regimens (either dabrafenib and trame-
tinib or vemurafenib and cobimetinib) achieve objec-
tive response rates (RRs) of 68–70% as compared with
approximately 50% with BRAFi monotherapy [3,4].
Medianprogression-freesurvival(PFS)rangesbetween
11and12monthswithcombinationtherapy,whereas
median overall survival (OS) has been reported at
22–26 months. A pooled analysis of 563 patients
treated with dabrafenib and trametinib showed that
after 3 years of follow-up, 23% of patients remained
progression-free. Typical adverse events associated
with BRAFi and MEKi occur regularly with both com-
bination regimens. Although efficacy is nearly identi-
cal, a recently published indirect comparative study
showed that combination treatment with vemurafe-
nib and cobimetinib is associated with a higher
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frequency of treatment-related adverse events than
treatment with dabrafenib and trametinib [5].
Efficacy and safety data of these two combina-
tion regimens point toward two major difficulties
clinicians face when treating melanoma patients
with BRAFi/MEKi combinations. First, despite excel-
lent initial RRs, treatment resistance and progres-
sion develops in almost 80% of patients within the
first 3 years of therapy [6
&
]. Second, treatment-
related adverse events occur frequently, leading to
dose interruptions or modifications in approxi-
mately half and treatment discontinuation in about
15% of all patients [5], which in turn may lead to
earlier resistance development and limit efficacy.
These problems support the need for second-gener-
ation BRAFi with modified pharmacological proper-
ties that may improve efficacy and tolerability. The
present review will focus on encorafenib (formerly
LGX818), the most intensively studied second-gen-
eration BRAFi in advanced melanoma to date.
PHARMACOLOGY
Encorafenib is an ATP-competitive v-Raf murine sar-
coma viral oncogene homolog (RAF) serine and
threonine kinase inhibitor selectively exhibiting anti-
proliferative effects in BRAF V600E-mutated cells. In
humans, oral encorafenib is highly bioavailable
(around 85%) and rapidly absorbed with a median
time to the maximum observed concentration (Tmax)
ofapproximately2-hpostdose [7
&&
]. Theplasmaelimi-
nation half-life of encorafenib is approximately
6 h. Elimination of encorafenib occurs mainly
through metabolism via cytochrome P450 (CYP)
enzymes (CYP3A4, CYP2C19 and CYP2D6). In turn,
encorafenib acts as a CYP enzyme inducer leading to a
consistent decrease in day 15 exposures by 30–60%
compared with those at day 1. Approximately 20
different metabolites of encorafenib have been identi-
fied and are excreted to equal parts in urine and feces.
Approximately only 2 and 5% of the absorbed encor-
afenib are excreted unchanged in urine and feces,
respectively. Food intake delays the absorption of
encorafenib, but does not alter overall drug exposure
[8]. Hence, encorafenib capsules are allowed to be
ingested regardless of food consumption.
In contrast to dabrafenib and trametinib, encor-
afenib shows a similar half-maximal inhibitory con-
centration (IC50) for wild-type BRAF, V600E-mutant
BRAF and v-Raf murine sarcoma viral oncogene
homolog C in cell-free biochemical assays [7
&&
,9].
Dabrafenib and trametinib have a lower IC50 espe-
cially for the wild-type BRAF protein which may be
relevant with regards to paradoxical MAP kinase
(MAPK) pathway activation which will be discussed
later on. Also, encorafenib is characterized by a sub-
stantially increased dissociation half-life (T1/2-diss)
from V600E-mutant BRAF of more than 30 h, as
compared with 2 and 0.5 h reported for dabrafenib
and vemurafenib, respectively (Fig. 1a and b; slow vs.
fast off-rate inhibitor). The long T1/2-diss, which was
confirmed in washout experiments in A375 mela-
noma cells (Fig. 1c) [10], translates into prolonged
target suppression and increased potency of encor-
afenib compared with established BRAFi. Target sup-
pression after BRAFi exposure can be depicted
through measurement of MEK phosphorylation as
seen in Fig. 1 comparing encorafenib and vemurafe-
nib. Increased potency of encorafenib results in IC50
values of 40 nmol/l or less in the majority of mela-
noma cell lines, whereas higher concentrations of
dabrafenib (<100 nmol/l), and especially vemurafe-
nib (<1mmol/l) are necessary to inhibit proliferation
of most cell lines [7
&&
]. In addition to its high potency,
encorafenib is also a very specificRAF inhibitor which
has been shown in a panel defining the inhibitory
profile of encorafenib against 99 kinases. In addition
to both the V600-mutated and wild-type BRAF-pro-
tein, encorafenib demonstrated potent inhibition
solely against CRAF (IC50¼8 nmol/l). Only two
other kinases were inhibited with IC50 less than
1mmol/l, namely Glycogen synthase kinase 3 beta
and c-Jun N-terminal kinase 2. In contrast, dabrafe-
nib showed activity against seven kinases other than
BRAF and CRAF with an IC50 of less than 100 nm in a
panel of 270 kinases [11].
Insummary,classicpharmacokineticandpharma-
codynamic properties such as Tmax and elimination
half-lifereflectthemetabolismofthedruginbloodand
tissue. However, this does not automatically reflect
KEY POINTS
 Combination therapy with BRAF and MEKi (either
vemurafenib and cobimetinib or dabrafenib and
trametinib) is the most established first-line treatment
option besides immunotherapy in BRAFV600-mutated
melanoma.
 Encorafenib (LGX818), a second-generation BRAF
inhibitor, is characterized by distinct pharmacological
properties, in particular a substantially prolonged
dissociation half-life of more than 30h.
 Pharmacological modifications may lead to increased
on-target effects (efficacy) and decreased off-target
effects (adverse events) with encorafenib.
 The phase III COLUMBUS trial showed superior efficacy
data of encorafenib over vemurafenib monotherapy.
Combination of encorafenib with the MEKi binimetinib
allowed for increased doses of encorafenib and further
increased efficacy in terms of RR and progression-free
survival.
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bindingtoandinhibitionofthetargetmolecule(s).The
value of drug dissociation properties, represented by
the T1/2-diss, is often underestimated. EC50, the half
maximum effective concentration integrates informa-
tionbothaboutassociation(measuredbytheIC50)and
dissociation (T1/2-diss). In the context of BRAF inhibi-
tion, EC50 can be determined by measurement of
either phosphorylated MEK or phosphorylated ERK
(pERK). Washout experiments in melanoma cells
showedthatthepERKEC50ofencorafenibonlyshifted
two-fold after washout compared with 14-fold and 23-
foldfordabrafenibandvemurafenib, respectively [7
&&
].
The substantially increased T1/2-diss of encorafenib is
ofclinical importance,asalongerT1/2-dissmaypoten-
tially translate into an increased efficacy (on-target
effect) while reducing toxicity (by avoiding or attenu-
ating off-target effects), thus improving the overall
benefit–risk ratio of the substance.
PARADOXICAL MAP KINASE PATHWAY
ACTIVATION AND RELATED ADVERSE
EVENTS
Class specific sideeffectsofBRAFiare inpartexplained
by the paradoxical activationof the MAPKpathway in
BRAF wild-type cells in various tissues. V600-mutated
BRAF typically acts as a constitutively active mono-
mer in the presence of low cellular rat sarcoma viral
oncogene homolog (RAS)-guanosine triphosphate
(GTP) levels and is specifically inhibited by estab-
lished BRAFi in its monomer confirmation [12
&&
].
Wild-type BRAF signaling, in contrast, is facilitated
by dimerization, either forming homodimers or het-
erodimerswithCRAF.SocalledaC-OUTBRAFisuchas
vemurafenib, dabrafenib and also encorafenib are not
only incapable of inhibiting dimerized RAF isoforms,
which explains why RAF dimerization is a known
resistance mechanism to BRAFi therapy [13]; these
inhibitors also promote RAF–RAS–GTP interaction
and RAF dimerization through allosteric changes in
the wild-type BRAF protein, leading to paradoxical
MAPK pathway activation especially in cells with
preexisting RAS mutations [12
&&
]. Quick dissociation
orshortT1/2-dissrequires frequentandhighdosingof
the inhibitor and may thus enhance these effects.
Along these lines, Adelmann et al. [14
&
] have recently
introduced a ‘paradox index’ to describe the thera-
peutic window of different BRAFi. This index was
defined as the paradox pERK activation EC80 (con-
centration leading to an eighty percent pERK
FIGURE 1. Increased dissociation half-life of encorafenib leads to prolonged target-inhibition. Left-sided graphs illustrating the
pharmacokinetic and pharmacodynamic differences between fast (a) and slow (b) off-rate inhibitors with short and long
dissociation half-lives, respectively. Experiments in A375 (BRAF-mutated) melanoma cell xenografts in mice confirmed
classification of PLX4032 (vemurafenib) and LGX818 (encorafenib) into the respective groups (aþb, right-sided graphs).
Phosphorylated MEK inhibition was used as a surrogate for target (mutated BRAF protein)-inhibition. Washout experiments in
A375 cells showed sustained target-inhibition even at low encorafenib doses (c). In contrast, sustained inhibition was only
seen with maximal doses of vemurafenib (d). Adapted with permission [10].
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activation) in a RAS-mutated cell line divided by the
IC80 against the BRAFV600-mutated A375 melanoma
cell line. A larger index hence is a surrogate for a better
benefit–risk ratio or more positive relation between
on-target and off-target effects of a BRAFi. Encorafe-
nib,dabrafenibandvemurafenibachievedanindexof
50, 10 and 5.5, respectively. Clinically this is in line
with the observation that development of cutaneous
squamouscell carcinoma(cSCC)orkeratoacanthoma
– the adverse event most clearly attributed to para-
doxical MAPK pathway activation – appears to be
more frequent with vemurafenib (18–19%
[1,15,16]) than with dabrafenib (6–10% [2,17,18])
and encorafenib (4% [7
&&
]). Corresponding, also pre-
clinical studies by Stuart et al. [10] showed that, in
contrast to both vemurafenib and dabrafenib, the
potential surrogate of cSCC in the mouse model –
gastric hyperplasia – does not even occur at the most
efficacious dose of encorafenib, which again points to
its wide therapeutic window with lower paradoxical
MAPK pathway activation. A recent analysis of 74
melanoma patients treated with encorafenib mono-
therapy or encorafenib and the MEK-inhibitor bini-
metinib at our institution [19] could alsoconfirm that
hyperproliferativeadverseeventssuchascSCCare less
frequent with encorafenib than with other BRAFi. In
contrast, our results show that inflammatory adverse
events such as palmoplantar hyperkeratosis or dyses-
thesiaseemtooccurmorefrequentlyparticularlywith
encorafenib monotherapy.
In addition to class effects responsible for
adverse events observed with most available BRAFi
at similar frequencies, vemurafenib and dabrafenib
have been associated with peculiar molecule-spe-
cific adverse events. These include photosensitivity
with vemurafenib and pyrexia with dabrafenib.
Both of these adverse events can substantially
impact drug tolerability and patients ‘quality of
life’. Low rates of photosensitivity and pyrexia
reported with encorafenib in monotherapy or
Table 1. Summary of adverse events in encorafenib-containing arms of the phase III COLUMBUS-trial
Combo450,
n¼192
Combo300,
n¼257
Enco300
(parts 12, n¼276)
Median duration of exposure (weeks) 51 52.1 31.5
Type of AE (%) Any grade Grade 3/4 Any grade Grade 3/4 Any grade Grade 3/4
Nausea 41 2 27 2 36 3
Diarrhea 36 3 28 2 12 1
Vomiting 30 2 15 <1 25 4
Fatigue 29 2 22 1 26 1
Arthralgia 26 1 22 1 43 8
Increased CK 23 7 20 5 1 0
Rasha 23 1 15 1 43 5
Headache 22 2 12 <1 26 3
Pyrexia 18 4 17 0 16 1
Increased GGT 15 9 14 5 11 4
Myalgia 14 0 14 <1 27 8
Alopecia 14 0 13 0 49 <1
Hyperkeratosis 14 1 10 0 39 3
Dry skin 14 0 8 0 28 0
Transaminases increased 13 6 14 5 5 1
Retinal pigment epithelial detachment 13 2 9 <1 1 0
Palmoplantar keratoderma 9 0 7 <1 24 1
Left ventricular dysfunction 8 2 6 1 3 1
Palmoplantar erythrodys-esthesia syndrome 7 0 4 <1 47 11
Photosensitivity 5 1 2 0 4 0
Secondary nonmelanoma skin neoplasms 4 0 6 1 10 1
AE grades were classified as defined by the National Cancer Institute Common Terminology Criteria. AE, adverse event; CK, creatine kinase; Combo300,
encorafenib 300mg once dailyþbinimetinib 45mg twice daily; Combo450, encorafenib 450mg once dailyþbinimetinib 45mg twice daily; Enco300,
encorafenib 300mg once daily monotherapy; GGT, Gamma-glutamyltransferase.
aThe term ‘rash’ included unspecified, local or generalized, erythematous, macular, papular, maculopapular, dermatitic, follicular, vesicular, psoriasiform and
pustular skin eruptions.
Adapted with permission [20
&
,21
&
].
Melanoma and other skin neoplasms
128 www.co-oncology.com Volume 30  Number 2  March 2018
combination therapy (Table 1) may contribute to an
improved safety profile in comparison with
established BRAFi.
SENESCENCE VS. APOPTOSIS:
ADVANTAGE OR DISADVANTAGE?
Another particular molecular feature of encorafenib
is its ability to induce cellular senescence accompa-
nied by autophagy, but not apoptosis, in BRAFV600E-
mutated melanoma cells [22
&
]. Cellular senescence
and autophagy have also been described in mela-
noma cells after vemurafenib treatment, but, in con-
trast toencorafenib,only inaddition to the induction
of apoptotic cell death [23,24]. It is currently unclear,
howthe induction of cellular senescence and autoph-
agy in encorafenib-treated melanoma cells translates
clinically in terms of encorafenib efficacy and devel-
opment of treatment resistance, as both cytoprotec-
tive and cytotoxic roles of autophagy have been
postulated in cancer therapy [25]. For vemurafenib
in particular, autophagy has been proposed as a
mechanism of adaptive treatment resistance [24].
Corresponding, combination ofBRAF andautophagy
inhibition was shown topromote tumor regression in
vemurafenib-resistant melanoma xenografts [24].
Borst et al. [26
&&
] recently investigated single mela-
noma cell clones responding to vemurafenib treat-
ment with either cell cycle arrest (senescence) or
apoptosis. Differential gene expression analysis
revealed a loss of the apoptosis-related gene BCL2-
Interacting Killer (BIK) in those cell clones undergo-
ing senescence. Moreover, histone deacetylase
(HDAC) inhibitor treatment was shown to reverse
epigenetic silencing of BIK mRNA expression in these
cells, subsequently leading to increased rates of apo-
ptotic cell death. As a potential molecule specificity
concerning the induction of senescence and autoph-
agy after treatment with different BRAFi is conceiv-
able, similar experiments with encorafenib are
necessary to explore whether combining encorafenib
with HDAC or autophagy inhibitors may also lead to
increased apoptosis and/or decreased treatment resis-
tance in vitro.
DOSE DEPENDENCY IN BRAF INHIBITORS
THERAPY: PRECLINICAL AND CLINICAL
DATA
Delord et al. [7
&&
] recently reported on an extensive
phase I dose-escalation and dose-expansion study
investigating encorafenib monotherapy in BRAF
V600-mutated melanoma. This study also included
biochemical assays and preclinical experiments in
cell lines and tumor xenografts in mice. Some of
the preclinical results have also been described in
previous sections of the present review. Mouse xeno-
graft studies by Delord in BRAF V600E-mutated A375
and HMEX1906 models showed that encorafenib
effectively inhibits tumor growth at doses as low as
5 mg/kg twice daily (BID). Similar results with vemur-
afenib and dabrafenib were demonstrated at doses of
60 mg BID and 100 mg once daily. For encorafenib,
the authors further showed that increased dosesup to
20 mg/kg are necessary to prevent resistance devel-
opment and achieve extended survival in continu-
ous dosing experiments in xenografted mice.
Preclinically, this finding suggests clear dose-depen-
dency of encorafenib efficacy. The clinical part of the
same study included a dose-escalation and a dose-
expansion cohort consisting of 54 and 35 patients,
respectively. About half of the patients in both
cohorts had already undergone pretreatment with
a BRAF-inhibitor. Encorafenib 450 mg once daily was
defined as the maximum tolerated dose (MTD). Due
to frequent occurrence of dose limiting toxicities in
patients receiving the MTD in the dose-expansion
cohort, 300 mg once daily evolved as the recom-
mended phase 2 dose for encorafenib monotherapy.
In line with preclinical findings, encorafenib was
able to induce tumor regression over a wide dose
range. Efficacy analysis yielded an overall RR
of 60% in BRAFi-naı¨ve patients in both the dose-
escalation cohort (all doses) and the dose-expansion
cohort (450 or 300 mg once daily). The RR in BRAFi-
pretreated patients was 10 and 22% in these cohorts,
respectively. Median time between prior BRAFi ther-
apy and the start of encorafenib was only slightly
longer than 5 weeks (38.5 days), which should par-
tially explain the modest RR in BRAFi-pretreated
patients. In contrast, Schreuer et al. [27
&
] recently
reported a RR of 32% for the combination of dabra-
fenib and trametinib in 25 BRAFi (þMEKi)-pretreated
patients. However, patients in this cohort had been
off BRAFi treatment for a period of at least 12 weeks.
The median PFS in treatment-naı¨ve patients in the
dose-expansion phase (n¼18) reported by the
Delord group was 12.4 months (95% confidence
interval, 7.4-not reached), which appears to be
considerably longer compared to what has been
reported previously for BRAFi monotherapy
[1,2,7
&&
]. Most frequent drug-related adverse events
occurring with encorafenib monotherapy included
myalgia, nausea, palmoplantar erythrodysesthesia,
arthralgia, alopecia and hyperkeratosis amongst
others. As discussed earlier, cSCC was rare (3–4%
of patients). Of note, transient Bell’s palsy was
reported in 8% of patients treated with encorafenib,
whereas it has rarely been reported in association
with other BRAFi [28].
As combination therapy with BRAFi and MEKi
has become the predominant strategy targeting
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BRAF-mutant advanced melanoma, encorafenib
has also been investigated in combination with
the MEKi binimetinib. We have recently reviewed
the development of binimetinib [29
&
] and reported
on its role in Neuroblastoma RAS viral oncogene
homolog (NRAS)-mutated melanoma elsewhere
[30
&
]. Based on data showing an additional effect
on treatment response duration by combining
encorafenib and binimetinib in a BRAF V600E-
mutant melanoma mouse model, this combination
regimen was first investigated in a phase 1b/2 clini-
cal study including 23 melanoma patients [31]. As
seen with other BRAFi/MEKi combinations, addi-
tion of a MEKi reduced the occurrence of on-target
BRAFi-related – that is cutaneous – adverse events,
subsequently allowing for higher dosing of the
BRAFi. Hence, the recommended phase 2 doses of
encorafenib and binimetinib were defined at 450/
600 mg once daily and 45 mg BID, respectively.
Preliminary efficacy data were promising with eight
of nine patients with BRAFi-naı¨ve melanoma show-
ing an objective response to combination therapy.
These results led to the initiation of the phase
3 COLUMBUS trial (Combined LGX818 Used
with MEK162 in BRAF Mutant Unresectable Skin
Cancer).
Part 1 of the COLUMBUS trial compared encor-
afenib at a dose of 450 mg once daily and binime-
tinib 45 mg BID with BRAF-inhibitor monotherapy
with either encorafenib 300 mg once daily or
vemurafenib 960 mg BID [20
&
]. Randomization
occurred in a 1 : 1: 1 fashion. The total patient pop-
ulation of 577 patients was further stratified by
American Joint Committee on Cancer stage, East-
ern Cooperative Oncology Group status, BRAF
mutation subtype (V600 E or K) and prior first-line
immunotherapy. Only 5% of all patients were pre-
treated with immunotherapy (either ipilimumab or
a pharmacodynamic-1-antibody). The primary end-
point of the study could be reached with median PFS
being significantly higher in the combination arm
than the two monotherapy arms [14.9 vs. 9.6 vs. 7.3
months (combination vs. encorafenib vs. vemura-
fenib), hazard ratio 0.54 for combination vs. vemur-
afenib (P¼0.001) and 0.75 for combination vs.
encorafenib (P¼0.051), Fig. 2]. Confirmed objec-
tive RRs by central review were 63, 51 and 40%
for combination, encorafenib and vemurafenib
(75, 58 and 49% by local review), whereas median
duration of response was 16.2., 14.8 and 8.4
months, respectively. The PFS benefit with combi-
nation treatment was consistent through most pre-
defined subgroups, especially in comparison with
vemurafenib. Notably, this was the first clinical trial
to show a significant difference between two differ-
ent BRAF-inhibitors administered as monotherapy,
once again pointing toward a superior potency of
encorafenib.
Part 2 of the COLUMBUS trial, most recently
reported on in September 2017 [21
&
], was designed
to independently evaluate the contribution of bini-
metinib to the efficacy of the encorafenib/binime-
tinib combination by comparison of encorafenib
monotherapy at 300 mg once daily with the com-
bination of encorafenib 300 mg once daily and
binimetinib 45 mg BID. The combination cohort
included 258 patients, 86 additional patients were
randomized in the monotherapy arm, adding up to
a total of 280 patients treated with encorafenib
300 mg monotherapy in parts 1 and 2 of the study.
Intriguingly, the results of part 2 again point
toward the preclinically observed and earlier men-
tioned dose dependency of encorafenib efficacy.
The combination regimen containing the
decreased encorafenib dose of 300 mg (combina-
tion 300) was able to retain a significant improve-
ment in PFS compared with encorafenib
monotherapy (12.9 vs. 9.2 months, hazard ratio
0.77, P¼0.029). Yet, the median PFS decreased
from 14.9 months with the combination 450
(450-mg encorafenib, 45-mg binimetinib) to 12.9
months with the combination 300 regimen. Con-
cerning safety, the combination 300 regimen was
associated with a slightly reduced occurrence of
National Cancer Institute Common Terminology
Criteria grade 3/4 adverse events (47 vs. 58% with
combination 450). However, the proportion of
adverse events leading to dose discontinuation
(13% with both regimens) or dose interruption/
modification (45 vs. 48%) remained relatively
unchanged. In both parts of the COLUMBUS study,
grade 3/4 adverse events were slightly less frequent
with combination therapy than BRAFi monother-
apy (58/47% with combination 450/300, 63% with
both encorafenib and vemurafenib). Treatment dis-
continuation due to adverse events was necessary
in a similar proportion (13%) of patients in all
treatment arms containing encorafenib in mono-
or combination therapy. A slightly larger propor-
tion of patients treated with vemurafenib (17%)
had to discontinue treatment due to adverse events.
Similar to what is known from other combination
therapy studies [3,4], typical BRAF-inhibitor-
related adverse events such as arthralgia, hyperker-
atosis or other dermatologic adverse events
occurred less frequently when combining BRAFi
and MEKi treatment. In turn, typical MEK-inhibi-
tor-associated toxicities such as increase of blood
creatine kinase or ocular toxicities were mainly
reported in combination patients. A summary of
the most frequent adverse events in the COLUM-
BUS trial can be found in Table 1.
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CONCLUSION AND FUTURE PERSPECTIVES
The BRAFi encorafenib, particularly in combination
with the MEK-inhibitor binimetinib, is evolving as a
new therapeutic option in BRAF-mutated advanced
melanoma. In the light of the promising efficacy
data outlined above, including an unprecedented
median PFS of 14.9 months with encorafenib/bini-
metinib combination therapy, OS data of the
COLUMBUS trial are eagerly expected by the mela-
noma community. Owing to its unique design, the
COLUMBUS trial is the first phase 3 study demon-
strating a clinical dose-dependency of BRAFi effi-
cacy. For other BRAFi, particularly vemurafenib,
such an exposure–response relationship has also
been suggested, but not clearly proven to date
[32]. Further research on this topic is necessary,
given the relatively high proportion of dose mod-
ifications when treating patients with BRAFi in rou-
tine practice, which may impair treatment efficacy.
The distinct pharmacological properties of encora-
fenib are thought to contribute both to improved
efficacy (enhanced on-target effect) and better tol-
erability as a result of less paradoxical MAPK path-
way activation combined with a reduction of off-
target effects due to high specificity. In conclusion,
encorafenib (combined with binimetinib) is
expected to emerge as a valuable alternative to
established BRAFi/MEKi combinations in the near
future. Further clinical studies including encorafe-
nib and binimetinib are already recruiting patients
to investigate the potential of sequencing or com-
bining the BRAFi/MEKi combination with immune
checkpoint inhibition (SECOMBIT and IMMU-TAR-
GET – ClinicalTrials.gov Identifiers: NCT02631447
and NCT02902042, respectively).
Representing the next step in the development
of targeted melanoma therapies, a subsequent gen-
eration of BRAFi, so-called paradox breakers, has
FIGURE 2. Kaplan–Meier estimates of progression-free survival in the four different treatment arms of the phase III
COLUMBUS trial. Part 1 of the trial investigated monotherapy with encorafenib 300mg once daily or vemurafenib 960mg
twice daily and combination therapy with encorafenib 450mg once dailyþbinimetinib 45mg twice daily. Median
progression-free survival was significantly longer with encorafenib 300mg compared with vemurafenib (a) and with
encorafenib 450mg once dailyþbinimetinib 45mg twice daily compared with either vemurafenib (b) or encorafenib 300mg
(c). Part 2 of the trial compared progression-free survival between combination therapy with encorafenib 300mg once daily
plus binimetinib 45mg twice daily and encorafenib 300mg, again showing superior progression-free survival with
combination therapy (d). CI, confidence interval; HR, hazard ratio; P, nominal P value. Adapted with permission [20&,21&].
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been developed [33] and may further improve BRAFi
efficacy. As paradoxical MAPK pathway activation
does not only account for certain BRAFi-related side
effects, but is also a known mechanism of acquired
BRAFi treatment resistance [34
&
], these molecules,
such as PLX8394, do not induce paradoxical ERK
phosphorylation in BRAF wild-type cells at all [14
&
]
and have shown preclinical efficacy in different
tumor cell lines resistant to established BRAFi
[35
&&
,36
&&
]. A phase 1/2a study assessing the safety,
pharmacokinetics and pharmacodynamics of
PLX8394 in patients with BRAF-mutated tumors
including melanoma is already ongoing (Clinical-
Trials.gov Identifier: NCT02428712).
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